Plain-English translation of NCT05534646 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining apalutamide with a new medication called works better than apalutamide alone for men with advanced prostate cancer that has stopped responding to other hormone-blocking drugs. The study will first carefully check that the combination is safe in a small group of patients, then expand to test whether adding the new medication helps more men live longer without their cancer getting worse.
Many men with advanced prostate cancer eventually stop responding to standard hormone-blocking treatments, and doctors need better options. This trial is designed to see if this medication combination can help patients whose cancer has become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
You would start by taking apalutamide alone while doctors monitor your response and safety. If your cancer continues to progress, you would then receive the combination of apalutamide plus the new medication. The study includes regular visits for blood tests, imaging scans, and check-ins with your care team to watch for side effects and measure how well the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States